About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010

Advertisement


Quark Pharmaceuticals, Inc.	The Ruth Group (investors / media)
Juliana Friedman	Sara Pellegrino / Jason Rando
+972 89 30 5111	(646) 536-7002 / 7025
[email protected]	[email protected]
	[email protected]

Sponsored Post and Backlink Submission

Latest Press Release on Drug News

41st International Conference on Drug Discovery and Drug delivery system

On behalf of the organizing committee its great pleasure to invite to all attendees of the "41st International Conference on Drug Discovery and Drug Delivery System" taking place on November...

London Research & Pharmaceuticals presents the Advancement of LRP-661, their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), hig...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

Provides MarVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 15, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq...

SparX Group Announces First Patient Dosed with SPX-303 Injection, the First in Its Class of anti-LILRB2/PD-L1 Bispecific Antibody Drugs

CHICAGO , April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has bee...

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Provides SuVax™ Heat Stable Vaccine Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , April 11, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: S...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close